SCHEDULE: Wellington Biomedical Discloses 9.99% Stake in ProMIS Neurosciences

Wellington Biomedical Innovation Master Investors (Cayman) II, L.P. has reported a 9.99% beneficial ownership stake in ProMIS Neurosciences, Inc. common stock.

Summary

• Wellington Biomedical Innovation Master Investors (Cayman) II, L.P. reported beneficial ownership of 895,877 shares of ProMIS Neurosciences, Inc. common stock.
• This represents 9.99% of the issuer's outstanding common stock.
• The ownership comprises 696,378 directly held shares and 199,499 shares underlying warrants.
• An additional 496,879 shares underlying warrants are excluded from beneficial ownership due to an issuance limitation preventing the holder from exceeding 9.99% ownership.
• The ownership percentage is based on approximately 8,967,740 shares of common stock outstanding, which includes 2,152,444 shares after a 1-for-25 reverse stock split effective November 28, 2025, and 6,815,296 shares issued as of February 3, 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as a specialized institutional investor has taken a significant stake, implying confidence in ProMIS Neurosciences' future, although the filing itself is purely factual.

Positives

• A significant institutional investor, Wellington Biomedical Innovation Master Investors (Cayman) II, L.P., has taken a substantial 9.99% stake in ProMIS Neurosciences, Inc., indicating confidence in the company's long-term prospects.
• The investment includes both direct shareholdings and warrants, suggesting a strategic interest in potential future upside.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that a significant stake by a specialized biomedical innovation fund like Wellington Biomedical Innovation Master Investors (Cayman) II, L.P. in a neuroscience company often signals a belief in the company's pipeline, technology, or market potential within the biotechnology sector. This type of investment can be seen as a vote of confidence, potentially attracting further investor interest in ProMIS Neurosciences, Inc.

Comparison to Industry Standards

• This filing reports a beneficial ownership stake, which is a standard disclosure requirement for institutional investors exceeding 5% ownership.
• The 9.99% stake is just below the 10% threshold that would typically trigger additional reporting requirements (e.g., Schedule 13D if the intent was to influence control), suggesting a passive investment strategy by Wellington Biomedical.
• Comparable situations involve other specialized funds taking significant, passive stakes in emerging biotech or pharmaceutical companies, often indicating a long-term investment horizon based on scientific advancements or clinical trial progress.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor's stake could be viewed positively, potentially increasing investor confidence and attracting more capital.
• Employees: No direct impact mentioned, but increased investor confidence could indirectly support company stability and future growth initiatives.
• Customers/Suppliers/Creditors: No direct impact mentioned in this filing.

Key Dates

Recommendation

The disclosure of a significant 9.99% stake by a specialized institutional investor like Wellington Biomedical is generally a positive indicator, suggesting confidence in ProMIS Neurosciences. However, a Schedule 13G filing is a passive ownership report and does not provide new operational or financial data to warrant a 'buy' recommendation without further fundamental analysis. The investment by a sophisticated player suggests the stock is worth holding for those already invested, and potentially researching for new investors, but it's not a direct catalyst for immediate strong upward movement without additional news.

Keywords

ProMIS Neurosciences, Wellington Biomedical Innovation Master Investors, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Biotechnology, Neurosciences, Warrants, Equity Stake